Technical and compliance support for small and mid-size pharma
Formulation problems, unvalidated methods, quality-system gaps and safety obligations slow small pharma teams down. We prepare the technical work and gap assessments that move them forward, virtually and worldwide.
What we do
What we prepare for pharmaceutical teams
Each item links to a service page with deliverables, inputs and boundaries. We prepare technical evidence, plans and strategy. We do not certify products, approve submissions or give legal opinions.
Formulation development
Root-cause work on solubility, crystallization and stability, solvent systems for topical products, and stability-study design.
Formulation developmentAnalytical methods
Method development plans, validation against ICH Q2(R2), specifications and extractables and leachables study plans.
Assay developmentGMP and GxP gap assessment
Gap assessments against GMP, GLP and ISO 13485 expectations, plus data-integrity review of electronic records against ALCOA+.
GMP and GxP complianceInspection readiness
Mock inspections, inspection-room process and staff training, and response plans for inspection observations.
Inspection readinessPharmacovigilance
Safety system and PSMF design, outsourcing oversight and routine signal screening. We do not serve as your QPPV.
PharmacovigilanceCompetitive intelligence
Pipeline and trial-registry tracking, technology landscapes and monthly literature digests that a scientist verifies.
Competitive intelligenceLaunch and market-access questions are covered under commercialization and regulatory and market access.
Illustrative situations
Problems we are typically asked to solve
These describe typical client types and problems. They are not client results, and we cannot promise outcomes, approvals or timelines.
A topical drug crystallizes in the tube
Specialty pharma company. A topical product forms crystals during storage, and the team is unsure whether the cause is supersaturation, the solvent system or the packaging.
How we advise. We review the composition, solubility data and storage conditions, then propose reformulation options and a stability-study design.
You receive. A root-cause assessment, ranked reformulation options and a stability test plan.
First marketing authorization, no safety system
Small drug sponsor. The company is approaching its first marketing authorization and has no pharmacovigilance system, safety database or core procedures.
How we advise. We design the system and PSMF, list the core SOPs, and set vendor selection and oversight criteria.
You receive. A system design, a draft PSMF outline, an SOP list and vendor criteria.
The first inspection is coming
Drug manufacturer. Staff have never faced an inspector, and the quality system has not been tested against inspection questions.
How we advise. We run a mock inspection with storyboards, record findings by risk and plan gap closure with your team.
You receive. A risk-ranked findings list, a remediation plan and staff briefing material.
Describe your pharmaceutical project
Send a general description of the problem and your deadline. A scientist follows up by email and prepares a written quote once the scope is clear.